Metaplastic Breast Carcinoma in U.S. Population: Racial Disparities, Survival Benefit of Adjuvant Chemoradiation and Future Personalized Treatment with Genomic Landscape.
Asad UllahJaffar KhanAbdul Qahar Khan YasinzaiKatharine TracyTena NguyenBisma TareenAndrea Agualimpia GarciaSaleh HeneidiSheila E SeguraPublished in: Cancers (2023)
Though rare, MBC is aggressive, with poor prognosis associated with high-grade tumors, metastasis, tumor size over 50 mm, and advanced age at the time of presentation. Overall, Black women had worse clinical outcomes. MBC is difficult to treat and carries a poor prognosis that affects various races disproportionately. Continued enhancement of treatment strategies to foster more individualized care as well as continued enrollment in clinical trials are needed to improve outcomes among patients with MBC.
Keyphrases
- poor prognosis
- high grade
- long non coding rna
- clinical trial
- affordable care act
- low grade
- healthcare
- palliative care
- polycystic ovary syndrome
- rectal cancer
- current status
- locally advanced
- phase ii
- pain management
- dna methylation
- copy number
- single cell
- metabolic syndrome
- gene expression
- combination therapy
- squamous cell carcinoma
- replacement therapy
- genome wide
- breast cancer risk